Evaluation of the urinary nuclear matrix protein (NMP22) as a tumour marker in bladder cancer patients

Nowotwory

Volumn 55, Issue 4, 2005, Pages 300-302

  Kowalska, Maria ^a   Kamińska, Janina ^a   Kotowicz, Beata ^a   Fuksiewicz, Małgorzata ^a   Rysińska, Alicja ^a   Demkow, Tomasz ^a   Kalinowski, Tomasz ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Bladder cancer; Cystoscopy; Nuclear matrix protein 22 (NMP22); Tumour markers

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROTEIN URINE LEVEL; URINALYSIS;

EID: 25444525156     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Didkowska J, Wojciechowska U, Tarkowski W et al. Nowotwory złośliwe w Polsce w 2000 roku. Warszawa: Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie, Krajowy Rejestr Nowotworów; 2004.
2. Poulakis V, Witzsch U, De Vries R et al. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. BJU International 2001; 88: 692-701.
3. Ponsky LE, Sharma S, Pandrangi L et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol 2001; 166: 75-8.
4. Oge O, Atsu N, Kendi S et al. Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer. Int Urol Nephrol 2001; 32: 367-70.
5. Gutierrez Banos JL, Rebollo Rodrigo MH, Antolin Juarez FM et al. NMP22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study. Urol Int 2001; 66: 185-90.
6. Giannopoulos A, Manousakas T, Gounari A et al. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and Urinary Bladder Cancer Antigen for primary and recurrent bladder tumours. J Urol 2001; 166: 470-5.
7. Casella R, Huber P, Blochlinger A Et al. Urinary level of Nuclear Matrix Protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor. J Urol 2000; 164: 1926-8.
8. Glas AS, Roos D, Deutekom M et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003; 169: 1975-82.
9. Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrago JM et al. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 2001; 92: 2820-8.
10. Shariat SF, Casella R, Wians FH Jr et al. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 2004; 45: 304-13.
11. Newling DW. Preventing recurrence and progression in superficial bladder cancer. Curr Opin Urol 1996; 6: 272-5.
12. Kurth KH, Denis L, Bouffioux C et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 31A: 1840-6.
13. Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002; 167: 80-3.
14. Van der Poel HG, Debruyne FM. Can biological markers replace cystoscopy? An update. Curr Opin Urol 2001; Sep:11: 503-9.
15. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999; 161: 62-5.